Medication info
Rinarem Extended Release Tablets 5/1000 mg (Linaagliptin, Metformin)

Rinarem Extended Release Tablets 5/1000 mg (Linaagliptin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›1000mg / 1 tabletLinagliptin Micronized›5mg / 1 tablet
Manufacturer / importer
Hanlim Pharmaceutical Co., Ltd.
Appearance
Pink, double convex, oval, extended-release film-coated tablets
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202400469 · Approved 2024.03.05 · Insurance code 645307060

Summary

Main use
Improvement of blood glucose control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5 mg and metformin hydrochloride extended-release 2000 mg. This medicine should be taken once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. Take 1 tablet of this medicine 5/1000 mg extended-release tablets once daily. Patients taking this medicine 2.5/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently treated with metformin: The initial total daily dose of this medicine is linagliptin 5 mg and metformin hydrochloride 1000mg; the dose of metformin hydrochloride may be increased gradually up to the maximum recommended daily dose of 2000 mg. 2. Patients treated with metformin - For patients who do not achieve adequate glycemic control with metformin monotherapy, the initial dose of this medicine should consist of a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients who do not achieve adequate glycemic control with metformin plus a sulfonylurea or metformin plus insulin, the initial dose of this medicine should be considered as a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose. When this medicine is coadministered with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia. - When switching from immediate-release metformin to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted as appropriate if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this medicine, use the same doses of linagliptin and extended-release metformin hydrochloride as the patient's current doses. Renal impairment Because dose adjustment according to renal function is necessary, assessment of renal function is recommended before starting this medicine and periodically thereafter. No dose adjustment is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), with creatinine clearance (CrCl) of 45mL/min or more and less than 60mL/min, or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or more and less than 60mL/min/1.73m2, this medicine may be used with dose adjustment of metformin hydrochloride as follows, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45mL/min or estimated glomerular filtration rate (eGFR) decreases to less than 45mL/min/1.73m2, this medicine must be discontinued immediately.

Ingredients

Manufacturer
Hanlim Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of blood glucose control in patients with type 2 diabetes mellitus

View approved original text

This medication is used to help patients with type 2 diabetes control their blood sugar levels. When used in conjunction with dietary and exercise therapies, it can manage blood sugar more effectively. The combination therapy of Linaagliptin and Metformin enhances blood sugar control effects, supporting a healthy lifestyle. Consistent use helps improve blood sugar control.

How to take

Adult dose

For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5 mg and metformin hydrochloride extended-release 2000 mg. This medicine should be taken once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. Take 1 tablet of this medicine 5/1000 mg extended-release tablets once daily. Patients taking this medicine 2.5/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently treated with metformin: The initial total daily dose of this medicine is linagliptin 5 mg and metformin hydrochloride 1000mg; the dose of metformin hydrochloride may be increased gradually up to the maximum recommended daily dose of 2000 mg. 2. Patients treated with metformin - For patients who do not achieve adequate glycemic control with metformin monotherapy, the initial dose of this medicine should consist of a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients who do not achieve adequate glycemic control with metformin plus a sulfonylurea or metformin plus insulin, the initial dose of this medicine should be considered as a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose. When this medicine is coadministered with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia. - When switching from immediate-release metformin to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted as appropriate if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this medicine, use the same doses of linagliptin and extended-release metformin hydrochloride as the patient's current doses. Renal impairment Because dose adjustment according to renal function is necessary, assessment of renal function is recommended before starting this medicine and periodically thereafter. No dose adjustment is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), with creatinine clearance (CrCl) of 45mL/min or more and less than 60mL/min, or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or more and less than 60mL/min/1.73m2, this medicine may be used with dose adjustment of metformin hydrochloride as follows, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45mL/min or estimated glomerular filtration rate (eGFR) decreases to less than 45mL/min/1.73m2, this medicine must be discontinued immediately.

Precautions

This medication is primarily used for the treatment of diabetes and works by regulating blood sugar with its two active ingredients. Caution is required as a rare side effect called lactic acidosis can occur when taking this medication. Lactic acidosis can result in a dangerous condition from excessive lactate accumulation in the body; if symptoms appear, consult a healthcare provider immediately. This medication should not be used in patients with certain diseases, severely impaired kidney function, acute liver dysfunction, alcohol dependence, or pregnant women. Since hypoglycemia may occur during treatment, especially when taken with other antidiabetic agents or insulin, careful monitoring of blood sugar levels is necessary. As kidney function may decline, regular blood tests to monitor kidney status are important. Patients with poor heart function should use this medication cautiously and, if experiencing acute myocardial infarction or heart failure, it is advisable not to use it. When iodinated contrast is used for radiographic examination, this medication should be stopped before and after the exam and resumed only after kidney function has normalized. Patients about to undergo surgery should discontinue this medication 48 hours prior to the procedure and resume it only after kidney function has recovered post-surgery. This medication should be swallowed whole and should not be crushed, chewed, or broken, as the tablet coating may be excreted without concern. This medication may lower vitamin B12 levels; thus, regular monitoring of vitamin B12 levels is necessary with long-term use. Rare side effects, such as acute pancreatitis or blistering dermatitis, may occur, so if severe abdominal pain or skin abnormality arises, consult a physician immediately. It is generally advisable not to use this medication during pregnancy and to avoid it while breastfeeding. Elderly patients may have decreased kidney function; hence, evaluation of kidney function and dosage adjustments are necessary prior to use. This medication can interact with other drugs, so if taking other medications, inform your physician or pharmacist. In case of overdose, this medication may not be fully absorbed by the gastrointestinal tract, and immediate medical attention should be sought.

Side effects

Severe lactic acidosis, hypoglycemia, angioedema, urticaria, lactic acidosis, abnormal vitamin B12 absorption test, hypoglycemic syndrome, taste disorder, cough, decreased appetite, diarrhea, constipation, nausea, pancreatitis, vomiting, abdominal pain, oral ulcer, abnormal liver function test, hepatitis, itching, erythema, rash, erythema multiforme, severe joint pain with disability, rhabdomyolysis, increased lipase, increased amylase, nasopharyngitis, hypersensitivity reaction, constipation, upper abdominal pain, enterocolitis, intestinal obstruction, gastroenteritis, shingles, cystitis, acute pyelonephritis, bronchitis, vestibular neuronitis, sepsis, pneumonia, decreased appetite, dehydration, hyperglycemia, cerebral infarction, stuttering, Alzheimer-type dementia, chest pain, fever, facial edema, fatigue, chronic obstructive pulmonary disease, asthma, diabetic foot disease, skin lesions, liver metastasis, acute leukemia, basal cell carcinoma, non-small cell lung cancer, malignant pericardial effusion, gastric cancer, rectal cancer, pancreatic cancer, meniscal injury, pneumoconiosis, congestive heart failure, angina pectoris, acute myocardial infarction, unstable angina, cardiac arrest, diabetic retinopathy, acute kidney injury, end-stage renal disease, acute cholangitis, acute cholecystitis, cholangitis, dizziness, kidney transplant failure, anxiety, mood disorder, insomnia, depression, contusion, bone contusion, concussion, bone fracture, hand fracture, palpitations, dry eye, glaucoma, cataract, ocular discomfort, allergic conjunctivitis, polyuria, proteinuria, stress urinary incontinence, hematuria, hypotension, flushing, fatty liver disease, cholelithiasis, hearing loss, erectile dysfunction, goiter, reduced hemoglobin, increased serum potassium, increased serum creatinine, increased serum creatine phosphokinase activity, increased ALT, increased triglycerides, male-pattern baldness, hyperhidrosis, dermatitis, anxiety, confusion state, nocturia, dermatitis, hypertension

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture, at room temperature between 1 and 30 degrees Celsius. Storing it this way will help maintain its effectiveness and prevent deterioration.

Appearance and packaging

Appearance

Pink, double convex, oval, extended-release film-coated tablets

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.